HOME >> MEDICINE >> NEWS
First medication to target PCP addiction is reported by Arkansas researchers

Animal studies by researchers at the University of Arkansas for Medical Sciences (UAMS) used an antibody-based drug to provide immediate protection against the chronic abuse of phencyclidine (PCP). The studies mark the first time that a long-acting treatment has been developed to block or reduce the psychoactive effects of PCP in drug addicts, according to UAMS scientist S. Michael Owens, Ph.D. In earlier studies, he used a smaller fragment of the antibody to treat drug overdose.

Owens presented his findings here today at the national meeting of the American Chemical Society, the world's largest scientific society.

Owens said his new technique uses monoclonal antibodies-identical copies of animal antibodies cloned and reproduced in the laboratory-to prevent or slow the entry of PCP into the brain, where it produces its pleasurable effects. The ability to create huge quantities of these antibodies makes it possible to administer a very large dose in a single injection. In the animal studies, just one injection curbed the effects of PCP for at least two weeks-a period equivalent to one to two months in humans, Owens said.

This fast-acting therapy could make a profound difference in the way PCP addicts are treated, enabling doctors to offer addicts an effective anti-addiction medication that works immediately. By contrast, antibody-based approaches to creating vaccines entail weeks of waiting before benefits appear, Owens said.

PCP triggers hallucinations, psychotic behavior, violence, and even self-destruction.

In a 1997 NIDA survey of high school seniors, more than two percent of the students said they had used PCP in the preceding 30 days. "Young people are attracted to PCP even though they know how dangerous it is, because it is inexpensive and because it produces euphoria, hallucinations and a feeling of superhuman strength," said Owens.

The UAMS research is supported by grants from the National Institute for Drug Ab
'"/>

Contact: Charmayne Marsh
y_marsh@acs.org
202-872-4445
American Chemical Society
24-Aug-1999


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
(Date:8/22/2014)... Newport Hospital has again attained the distinguished Magnet ... (ANCC) Magnet Recognition Program. Considered the gold standard ... recognizes nursing excellence and professionalism. It is the ... unanimous decision to redesignate Newport Hospital was based ... standards of nursing practice. , "It is a ...
(Date:8/22/2014)... August 22, 2014 Home Care ... in-home care for seniors, is proud to announce the ... The upcoming webinar will feature Dr. Suzanne Steinbaum, attending ... Hill Hospital in New York City, National Spokesperson for ... The webinar will cover the issues surrounding women and ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Counseling may ... a large-scale review finds. Researchers analyzed 66 studies ... of whom were at high risk for drinking problems. ... session, while participants in the rest of the studies ... individual sessions. A counseling technique called motivational interviewing ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Inner city children have ... finds. Researchers followed 516 inner city children in four ... -- from birth until age 5 and found that at ... eggs or peanuts. Because only the three most common ... actual number of inner city youngsters with food allergies may ...
(Date:8/22/2014)... the previous few years, several breakthrough treatments have ... Patients who may benefit from these treatments can ... in their cancer. For example, patients whose lung ... ALK derive significant benefit from the drug crizotinib, ... are now attempting to replicate this success by ...
Breaking Medicine News(10 mins):Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... Cell Research Products: Opportunities, Tools & Technologies" report ... supply stem cell research products or you wish to ... and lucrative this market is. The authors know you ... more effectively to scientists, to generate improved revenues and ...
(Date:8/22/2014)... Research and Markets has announced ... Catheter Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Global and Chinese Intravenous Catheter Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
Cached News: